AKT1 and lung cancer: In exactly the same way, rapamycin sensitized crizotinib-resistant EML4-ALK+ lung cancer cells to ALK inhibition: Crizotinib alone did not affect ALK and AKT activity, but blocked the feedback activation from mTOR to AKT, when administered together with rapamycin [47].